1. Treatment of central precocious puberty and early puberty with GnRH analog in girls with Williams-Beuren syndrome.
- Author
-
Spielmann S, Partsch CJ, Gosch A, and Pankau R
- Subjects
- Adolescent, Body Height drug effects, Body Weight drug effects, Child, Female, Fertility Agents, Female administration & dosage, Humans, Leuprolide administration & dosage, Treatment Outcome, Fertility Agents, Female therapeutic use, Leuprolide therapeutic use, Puberty, Precocious drug therapy, Williams Syndrome drug therapy
- Abstract
Objective: Little has been published on treatment of precocious puberty in girls with Williams-Beuren syndrome (WBS), a condition occurring frequently in this group. We analyzed our own data on growth/age at menarche of now adult female patients with WBS being diagnosed with central precocious puberty or early puberty. Data of patients treated with gonadotropin-releasing hormone (GnRH) analog (n=13) were compared with those not treated (control group, n=11)., Patients: Longitudinal data on the somatic development of 24 now adult female patients were analyzed., Results: Medium final height was 157.2±6.5 cm compared to 151.4±5.6 cm in the control group. No significant difference could be found in the discrepancy of genetic target height and final height. Prepubertally girls were normal weight in both groups; in adulthood the majority of patients were overweight/obese. Menarche commenced 11 months after cessation of therapy., Conclusion: As already known from other studies, hormonal suppression via GnRH analog was well tolerated.
- Published
- 2015
- Full Text
- View/download PDF